The future of COVID-19 management: A spotlight on respirology
10 Jan 2024;
At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.
Indications/Uses : Adjunct to diet & maximally tolerated statin therapy for the treatment of adults w/ heterozygous familial hypercholesterolemia or established atherosclerotic CV disease who require additional lowering of LDL-C.
Indications/Uses : Adjunct to diet & maximally tolerated statin therapy for the treatment of adults w/ heterozygous familial hypercholesterolemia or established atherosclerotic CV disease who require additional lowering of LDL-C.
Contents : Per actuation (delivered dose, ex-actuator) Budesonide 160 mcg, glycopyrronium 7.2 mcg, formoterol fumarate dihydrate 5 mcg
Indications/Uses : Maintenance treatment for moderate to severe COPD in adults who are not adequately treated by a combination of an inhaled corticosteroid & a long-acting β2-agonist or combination of a long-acting β2-agonist & a long-acting muscarinic antagonist.
Sign Out
